TD Cowen analyst Phil Nadeau maintained a Buy rating on Galapagos (GLPG – Research Report) today. The company’s shares closed today at $37.04.
Nadeau covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Biogen, and BioMarin Pharmaceutical. According to TipRanks, Nadeau has an average return of 12.8% and a 48.90% success rate on recommended stocks.
Galapagos has an analyst consensus of Hold, with a price target consensus of $52.23.
See Insiders’ Hot Stocks on TipRanks >>
GLPG market cap is currently $2.2B and has a P/E ratio of -14.28.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galapagos (GLPG) Company Description:
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Read More on GLPG:
